Shandong University
sdu.edu.cnTotal trials
292
Active
34
Phase 3
21
Total enrollment
40,516,793
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 32 of 32 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| H. pylori eradication | — | — | — | — | — | 1 | |
| Gushen Antai Pill | — | — | — | — | — | 1 | |
| vonoprazan+amoxicillin | — | — | — | — | — | 1 | |
| vonoprazan+amoxicillin+tetracycline+bismuth | — | — | — | — | — | 1 | |
| Talniflumate | — | — | — | — | — | 1 | |
| Dexamethasone | — | — | 18 | ||||
| Recombinant Human Thrombopoietin | — | — | — | — | — | 3 | |
| Progesterone-modified natural cycle preparation for frozen embryo transfer | — | — | — | — | — | 1 | |
| Hormone replacement therapy cycle preparation for frozen embryo transfer | — | — | — | — | — | 1 | |
| High-Dose Dexamethasone Combined with Orelabrutinib | — | — | — | — | — | 1 | |
| High-Dose Dexamethasone Combined with Placebo | — | — | — | — | — | 1 | |
| Romiplostim N01 | — | — | — | — | — | 1 | |
| Niraparib | — | — | — | — | — | 1 | |
| Efbemalenograstim Alfa | — | — | — | — | — | 1 | |
| Rifampin | — | — | — | — | — | 1 | |
| Isoniazid | — | — | — | — | — | 1 | |
| Rifapentine | — | — | — | — | — | 1 | |
| Moxifloxacin | — | — | — | — | — | 1 | |
| Pyrazinamide | — | — | — | — | — | 1 | |
| Ethambutol | — | — | — | — | — | 1 | |
| diammonium glycyrrhizinate enteric-coated | — | — | — | — | — | 1 | |
| Shouhui Tongbian | — | — | — | — | — | 1 | |
| Anti-Infective Drugs | — | — | — | — | — | 2 | |
| Metformin pretreatment before ovarian stimulation | — | — | — | — | — | 1 | |
| Metformin pretreatment before endometrial preparation for frozen embryo transfer | — | — | — | — | — | 1 | |
| PD-1 inhibitor | — | — | — | — | — | 1 | |
| Terbinafine | — | — | — | — | — | 1 | |
| Piperacillin Sodium and Tazobactam Sodium for | — | — | — | — | — | 1 | |
| Blinatumomab | — | — | — | — | — | 1 | |
| Busulfan, Paclitaxel, Afatinib, Ceritinib, Crizotinib | — | — | — | — | — | 1 | |
| Increase the frequency and extended infusion time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda) 4.5g | — | — | — | — | — | 1 | |
| Extended Infusion Time of Piperacillin Sodium and Tazobactam Sodium for Injection (Bonda), 4.5g | — | — | — | — | — | 1 |
Next readouts
- 2021-08-21
- 2025-06-01
- 2025-10-01
- 2025-12
- 2025-12-31
- 2025-12-31
- 2026-02-28
- 2026-05-30
- 2026-06
- 2026-06-30
Top conditions
- Helicobacter Pylori Infection31
- Immune Thrombocytopenia29
- Artificial Intelligence14
- Gastric Intestinal Metaplasia11
- Helicobacter Pylori10
- Colorectal Neoplasms8
- Irritable Bowel Syndrome7
- Thrombocytopenia6
Frequently asked questions about Shandong University
- How many clinical trials does Shandong University have on ClinicalTrials.gov?
- Shandong University is listed as the lead sponsor on 292 clinical trials in ClinicalTrials.gov, 34 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Shandong University's trials are in Phase 3?
- 21 of Shandong University's trials are in Phase 3, spread across 32 active drug programs.
- What therapeutic areas does Shandong University focus on?
- Shandong University's most-studied conditions on ClinicalTrials.gov are Helicobacter Pylori Infection, Immune Thrombocytopenia, Artificial Intelligence, Gastric Intestinal Metaplasia, Helicobacter Pylori.
- When are Shandong University's next clinical trial readouts?
- Shandong University has 10 upcoming primary-completion readouts tracked here; the soonest is “A Multicenter Randomized Open-label Study of Diammonium Glycyrrhizinate Enteric-coated Capsule Plus DXM Versus DXM in Treatment of ITP”, expected around 2021-08-21.